Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melanoma Quantiferon: Cytokine Test for Checkpoint Inhibitor Response
NCT05649683Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jan 2023
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial in melanoma, sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Th1, Th2 and Th17 cytokine production correlate to the RECIST 1.1 tumoral response at 11 weeks. Started Jan 2023; status: recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT05649683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649683.